Camille Bedrosian

Camille Bedrosian serves as Chief Medical Officer at Amylyx Pharmaceuticals since November 2023. Prior to this role, Camille provided strategic guidance to clinical development and translational research programs as Strategic Development Advisor at Ultragenyx from January 2018 to November 2023, having previously held the position of Executive Vice President and Chief Medical Officer at the same company from January 2018 to May 2023. Camille's extensive experience in the pharmaceutical industry includes leadership roles at Alexion Pharmaceuticals, ARIAD Pharmaceuticals, and Wyeth, where responsibilities ranged from Senior Vice President to Therapeutic Area Head. Additionally, Camille has a strong academic background, including a medical degree from Harvard Medical School and faculty positions at Duke University Medical Center, contributing to clinical research and oncology.